abstract |
Described are uses of an agent that reduces B7-H1 interaction with PD-I, and particularly monoclonal antibodies that bind to B7-H1 and interfere with B7-H1 interaction with PD-I in combination with a vaccine to provide synergistic effects. The application provides methods of treatment and vaccination based on the combination of these compounds on T cell responses. |